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ABSTRACT 
Inflammatory bowel diseases are chronic gastrointestinal inflammatory disorders that affect millions of 
people worldwide. Genome-wide association studies have identified 200 inflammatory bowel disease-
associated loci, but few have been conclusively resolved to specific functional variants. Here we report 
fine-mapping of 94 inflammatory bowel disease loci using high-density genotyping in 67,852 
individuals. We pinpoint 18 associations to a single causal variant with greater than 95% certainty, and 
an additional 27 associations to a single variant with greater than 50% certainty. These 45 variants are 
significantly enriched for protein-coding changes (n= 13), direct disruption of transcription-factor 
binding sites (n=3), and tissue -specific epigenetic marks (n=10), with the last category showing 
enrichment in specific immune cells among associations stronger in Crohn's disease and in gut 
mucosa among associations stronger in ulcerative colitis. The results of this study suggest that high-
resolution fine-mapping in large samples can convert many discoveries from genome-wide association 
studies into statistically convincing causal variants, providing a powerful substrate for experimental 
elucidation of disease mechanisms. 
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Inflammatory bowel diseases (IBDs) are a group of chronic, debilitating disorders of the 
gastrointestinal tract with peak onset in adolescence and early adulthood. More than 1.4million people 
are affected in the USA alone
1
, with an estimated direct healthcare cost of US$6.3 billion per year. IBD 
affects millions worldwide, and is rising in prevalence, particularly in paediatric and non-European 
ancestry populations
2
. IBD has two subtypes, ulcerative colitis and Crohn's disease, which have 
distinct presentations and treatment courses. So far, 200 genomic loci have been associated with 
IBD
3,4
, but only a handful have been conclusively ascribed to a specific causal variant with direct 
insight into the underlying disease biology. This scenario is common to all genetically complex 
diseases, where the pace of identifying associated loci outstrips that of defining specific molecular 
mechanisms and extracting biological insight from each association. 
The widespread correlation structure of the human genome (known as linkage disequilibrium) often 
results in similar evidence for association among many neighbouring variants. However, unless 
linkage disequilibrium is perfect (r
2
 = 1), it is possible, with a sufficiently large sample size, to 
statistically resolve causal variants from neighbours even at high levels of correlation (Extended Data 
Fig. 1 and ref. 5). Novel statistical approaches applied to very large datasets that address this 
problem
6
 require that the highly correlated variants are directly genotyped or imputed with certainty. 
Truly high-resolution mapping data, when combined with increasingly sophisticated and 
comprehensive public databases annotating the putative regulatory function of DNA variants, are likely 
to reveal novel insights into disease pathogen-esis
7-9
 and the mechanisms of disease-associated 
variants. 
Figure 1 | Fine-mapping procedure and output using the SMAD3 region as an example, a, (1) 
We merge overlapping signals across methods; (2) we select a lead variant (black triangle) and 
phenotype (colour); and (3) we choose the best model. Details for each step are available in Methods, 
b, Example fine-mapping output. This region has been mapped to two independent signals. For each 
signal, we report the phenotype it is associated with (coloured), the variants in the credible set, and 
their posterior probabilities. AF, allele frequency. 
 
 
Genetic architecture of associated loci 
We genotyped 67,852 individuals of European ancestry, including 33,595 with IBD (18,967 Crohn's 
disease and 14,628 ulcerative colitis) and 34,257 healthy controls using the Illumina ImmunoChip 
(Extended Data Table 1). This genotyping array was designed to include all known variants from 
European individuals in the February 2010 release of the 1000 Genomes Project
10,11
 in 187 high-
density regions known to be associated with one or more immune-mediated diseases
12
. Because fine-
mapping uses subtle differences in strength of association between tightly correlated variants to infer 
which is most likely to be causal, it is particularly sensitive to data quality. We therefore performed 
stringent quality control to remove genotyping errors and batch effects (Methods). We imputed into this 
dataset from the 1000 Genomes Project reference panel
13,14
 to fill in variants missing from the 
ImmunoChip, or filtered out by our quality control (Extended Data Fig. 2). We then evaluated the 97 
high-density regions that had previous IBD associations
3
 and contained at least one variant showing 
significant association (Methods) in this dataset. The major histocompatibility complex was excluded 
from these analyses as fine-mapping has been reported elsewhere
15
. 
We applied three complementary Bayesian fine-mapping methods that used different priors and model 
selection strategies to identify independent association signals within a region, and to assign a 
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posterior probability of causality to each variant (Supplementary Methods and Extended Data Fig. 2). 
For each independent signal detected by each method, we sorted all variants by the posterior 
probability of association, and added variants to the 'credible set' of associated variants until the sum 
of their posterior probability exceeded 95%: that is, the credible set contained the minimum list of DNA 
variants that were >95% likely to contain the causal variant (Fig. 1). These sets ranged in size from 1 
to >400 variants. We merged these results and subsequently focused only on signals where an 
overlapping credible set of variants was identified by at least two of the three methods and all variants 
were either directly genotyped or imputed with INFO score >0.4 (Methods and Fig. 1). 
In 3 out of 97 regions, a consistent credible set could not be identified; when multiple independent 
effects exist in a region of very high linkage disequilibrium, multiple distinct fine-mapping solutions may 
not be distinguishable (Supplementary Note). Sixty-eight of the remaining 94 regions contained a 
single association, while 26 harboured 2 or more independent signals, for a total of 139 independent 
associations defined across the 94 regions (Fig. 2a). Only IL23R and NOD2 (both previously 
established to contain multiple associated protein-coding variants
16
) contained more than three 
independent signals. Consistent with previous reports
3
, the vast majority of signals were associated 
with both Crohn's disease and ulcerative colitis, although many of these had a significantly stronger 
association with one subtype. For the enrichment analyses below, we compared 79 signals that were 
more strongly associated with Crohn's disease with 23 signals that were more strongly associated with 
ulcerative colitis (the remaining 37 were equally associated with both subtypes, Supplementary Table 
1). 
Using a restricted maximum likelihood mixed-model approach
17
, we evaluated the proportion of total 
variance in disease risk attributed to these 94 regions and how much of that was explained by the 139 
specific associations. We estimated that 25% of Crohn's disease risk was explained by the specific 
associations described here, out of a total of 28% explained by these loci (correspondingly for 
ulcerative colitis: 17% out of 22%). The single strongest signals in each region contributed 76% of this 
variance explained and the remaining associations contributed 24% (Extended Data Fig. 3), 




Associations mapped to a single variant 
For 18 signals, the 95% credible set consisted of a single variant ('single variant credible sets'), and for 
24 others the credible set consisted of 2-5 variants (Fig. 2b). The single-variant credible sets included 
five previously reported coding variants: three in NOD2 (fsl007insC, R702W, G908R), a rare protective 
allele in IL23R (V362I), and a splice variant in CARD9 (c.IVS11+1G>C)
16,19
. The remaining single-
variant credible sets comprised three missense variants (1170V in SMAD3, 1923V in IFIH1, and 
N289S in NOD2), four intronic variants (in IL2RA,LRRK2, NOD2, and RTEL1/TNFRSF6B), and six 
intergenic variants (located 3.7kilobases (kb) downstream of GPR35; 3.9kb upstream of PRDM1; 
within a EP300 binding site 39.9kb upstream of IKZF1; 500 base pairs (bp) before the transcription 
start site of JAK2; 9.4kb upstream of NKX2-3; and 3.5kb downstream from HNF4A) (Table 1). Of note, 
while physical proximity did not guarantee functional relevance, the credible set of variants for 30 
associated loci now implicated a specific gene either because it resided within 50 kb of only that gene 
or had a coding variant with >50% probability—improved from only 3 so refined using an earlier 
HapMap-based definition. Using the same definitions, the total number of potential candidate genes 
was reduced from 669 to 233. Examples of IBD candidate genes clearly prioritized in our data are 
described in the Supplementary Box, and a customizable browser 
(http://flnemapping.broadinstitute.org/) is available to review the detailed fine-mapping results. 
 
Associated protein-coding variants 
We first annotated the possible functional consequences of the IBD variants by their effect on the 
amino-acid sequences of proteins. Thirteen out of 45 variants (Fig. 2c) that had >50% posterior 
probability were non-synonymous (Table 1), an 18-fold enrichment (enrichment P = 2 x 10
-13
, Fisher's 
exact test) relative to randomly drawn variants in our regions (Fig. 3a). By contrast, only one variant 
with >50% probability was synonymous (enrichment P= 0.42). All common coding variants previously 
reported to affect IBD risk were included in a 95% credible set, including IL23R (R381Q, V362I, and 
G149R); CARD9 (c.IVS11+1G>C andS12N); NOD2 (S431L, R702W, V793M, N852S, and G908R, 
fsl007insC); ATG16L1 (T300A); PTPN22 (R620W); and FUT2 (W154X). While this enrichment of 
coding variation (Fig. 3a) provided assurance about the accuracy of our approach, it did not suggest 
that 30% of all associations were caused by coding variants; rather, it was almost certainly the case 
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that associated coding variants had stronger effect sizes, making them easier to fine-map. 
Associated non-coding variants 
We next examined conserved nucleotides in high-confidence binding-site motifs of 84 transcription 
factor families
20
 (Methods). There was a significant positive correlation between transcription-factor 
motif disruption and IBD association posterior probability (P=0.006, logistic regression) (Fig. 3a), 
including three variants with >50% probability (two >95%). In the RTEL1/TNFRSF6B region, 
rs6062496 is predicted to disrupt a transcription-factor binding motif site (TFBS) for EBF1, a 
transcription factor involved in the maintenance of B-cell identity and prevention of alternative fates in 
committed cells
21
. A low-frequency (3.6%) protective allele at rs74465132 creates a binding site for 
EP300 less than 40 kilobase pairs (kbp) upstream of IKZF1. The third notable example of TFBS 
disruption, although not in a single variant credible set, is detailed in the Supplementary Box for the 
association at SMAD3. 
Recent studies have shown that trait-associated variants are enriched for epigenetic marks 
highlighting cell-type-specific regulatory regions
9,22,23
. We compared our credible sets with ChlP-seq 
peaks (chromatin immunoprecipitation followed by sequencing) corresponding to ChIP with H3K4mel, 
H3K4me3, and H3K27ac (shown previously
22,23
 to highlight enhancers, promoters, and active 
regulatory elements, respectively) in 120 adult and fetal tissues, assayed by the Roadmap 
Epigenomics Mapping Consortium
24
 (Fig. 3b). Using a threshold of P= 1.3 x 10
-4
 (0.05 corrected for 
360 tests), we observed significant enrichment of H3K4mel in 6 immune cell types and for H3K27ac in 
2 gastrointestinal (gut) samples (sigmoid colon and rectal mucosa) (Fig. 3b and Supplementary Table 
2). The subset of signals that were more strongly associated with Crohn's disease overlapped more 
with immune-cell chromatin peaks, whereas ulcerative colitis signals overlapped more with gut 
chromatin peaks (Supplementary Table 2). 
These three chromatin marks were correlated both within tissues (we observed additional signal in 
other marks in the tissues described above) and across related tissues. We therefore defined a set of 
'core immune peaks' for H3K4mel and 'core gut peaks' for H3K27ac as the set of overlapping peaks in 
all enriched immune cell and gut tissue types, respectively. These two sets of peaks were 
independently significant and captured the observed enrichment compared with 'control peaks' made 
up of the same number of ChlP-seq peaks across our 94 regions in non-immune and non-gut tissues 
(Fig. 3c, d). These two tracks summarized our epigenetic-GWAS overlap signal, and the combined 
excess over the baseline suggested that a substantial number of regions, particularly those not 
mapped to coding variants, may ultimately be explained by functional variation in recognizable 
enhancer/ promoter elements. 
 
Figure 2 | Summary of fine-mapped associations, a, Independent signals. Sixty-eight loci 
containing one association and 26 loci containing multiple associations, b, Number of variants in 
credible sets. Eighteen associations were fine-mapped to a single variant, and 116 to ≤50 variants, c, 
Distribution of the posterior probability of the variants in credible sets having ≤50 variants. 
 
 
Table 1 I Variants having posterior probability >50% 
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Variant Chr Position Ns Phe AF Prob INFO Func Annotation 
Signals mapped to a single variant 
rs7307562 12 40724960 2 CD 0.398 0.999 1  LRRK2 (intronic) 
rs2066844 16 50745926 10 CD 0.063 0.999 0.8 C NOD2 (R702W) 
rs2066845 16 50756540 10 CD 0.022 0.999 1 C NOD2 (G908R) 
rs6017342 20 43065028 2 UC 0.544 0.999 1 E HNF4A (downstream), Gut_H3K27ac 
rs61839660 10 6094697 2 CD 0.094 0.999 1 E IL2RA (intronic), lmmune_H3K4mel 
rs5743293 16 50763781 10 CD 0.964 0.999 1 C NOD2 (fs1007insC) 
rs6062496 20 62329099 1 IBD 0.587 0.996 1 T RTEL1-TNFRSF6B (ncRNAJntronic), 
EBF1 TFBS 
rs141992399 9 139259592 3 IBD 0.005 0.995 1 c CARD9 (1434+1G>C) 
rs35667974 2 163124637 1 UC 0.021 0.994 1 c IFIH1 (1923V) 
rs74465132 7 50304782 3 IBD 0.034 0.994 1 T,E IKZF1 (upstream), EP300TFBS, 
lmmune_H3K4mel 
rs4676408 2 241574401 1 UC 0.508 0.994 0.99  GPR35 (downstream) 
rs5743271 16 50744688 10 CD 0.007 0.993 1 C NOD2 (N289S) 
rs10748781 10 101283330 2 IBD 0.55 0.990 1 E NKX2-3 (upstream), Gut_H3K27ac 
rs35874463 15 67457698 2 IBD 0.054 0.989 1 C E SMAD3 (|170V), Gut_H3K27ac 
rs72796367 16 50762771 10 CD 0.023 0.983 1  NOD2 (intronic) 
rs1887428 9 4984530 1 IBD 0.603 0.974 0.97  JAK2 (upstream) 
rs41313262 1 67705900 5 CD 0.014 0.973 1 C IL23R (V362I) 
rs28701841 6 106530330 2 CD 0.116 0.971 1  PRDM1 (upstream) 
Signals mapped to 2-50 variants and the lead variant has posterior probability    50% 
rs76418789 1 67648596 5 CD 0.006 0.937 0.59 C IL23R (G149R) 
rs7711427 5 40414886 3 CD 0.633 0.919 1   
rs1736137 21 16806695 2 CD 0.407 0.879 1   
rs104895444 16 50746199 10 CD 0.003 0.865 1 C NOD2 (V793M) 
rs56167332 5 158827769 2 IBD 0.353 0.845 1  IL12B 
rs104895467 16 50750810 10 CD 0.002 0.833 1 C NOD2 (N852S) 
rs630923 11 118754353 2 CD 0.153 0.820 0.98   
rs3812565 9 139272502 3 IBD 0.402 0.815 1 Q eQTL of INPP5 in CD4 and CD8; 
CARD9 in CD14 
rs4655215 1 20137714 3 UC 0.763 0.784 1 E Gut_H3K27ac 
rs145530718 19 10568883 3 CD 0.023 0.762 0.97   
rs6426833 1 20171860 3 UC 0.555 0.752 1   
chr20:43258
079 
20 43258079 2 CD 0.041 0.736 0.88   
rs17229679 2 199560757 2 UC 0.028 0.716 1   
rs4728142 7 128573967 1 UC 0.448 0.664 1 E Immune_H3K4mel 
rs2143178 22 39660829 2 IBD 0.157 0.662 1 T, E NF-KB TFBS, Gut_H3K27ac 
rs34536443 19 10463118 3 CD 0.038 0.649 1 C TYK2 (P1104A) 
rs138425259 16 50663477 10 UC 0.009 0.648 0.92   
rs146029108 9 139329966 3 CD 0.036 0.643 0.92   
rs12722504 10 6089777 2 CD 0.26 0.615 1   
rs60542850 19 10488360 3 IBD 0.17 0.591 0.89   
rs2188962 5 131770805 1 CD 0.44 0.590 1 E,Q Gut_H3K27ac, eQTL of SLC22A5 in 
CD14, CD15 and IL 
rs2019262 1 67679990 5 IBD 0.4 0.586 1   
rs3024493 1 206943968 2 IBD 0.171 0.537 1 E Immune_H3K4mel 
rs7915475 10 64381668 3 CD 0.304 0.528 1   
rs77981966 2 43777964 1 CD 0.077 0.521 1   
rs9889296 17 32570547 1 CD 0.264 0.512 1   
rs2476601 1 114377568 1 CD 0.908 0.508 1 C PTPN22 (W620R) 
Chr, chromosome; Ns, number of independent signals in the locus; Phe, phenotype; AF, allele frequency; Prob, posterior 
probability for being a causal variant, INFO, imputation; Func, functional annotations: coding (C), disrupting transcription-factor 
binding sites (T), overlapping epigenetic peaks (E), and co-localization with eQTL(Q); CD, Crohn's disease; IBD, inflammatory 
bowel disease UC, ulcerative colitis 
 
 
Figure 3 | Functional annotation of causal variants, a, Proportion of credible variants that are 
protein-coding, disrupt/create TFBS or are synonymous, sorted by posterior probability. b, Epigenetic 
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peaks overlapping credible variants in cell and tissue types from the Roadmap Epigenomics 
Consortium
39
. Significant enrichment has been marked with asterisks. Proportion of credible variants 
that overlap (c) core immune peaks for H4K4mel or (d) core gut peaks for H3K27ac (Methods). In a, c 
and d, the vertical dotted lines mark 50% posterior probability and the horizontal dashed lines show 
the background proportions of each functional category. 
 
 
Overlap with expression quantitative trait loci 
Variants that change enhancer or promoter activity might change gene expression, and baseline 
expression of many genes has been found to be regulated by genetic variation
25-27
. Indeed, it has 
been suggested that these so-called expression quantitative trait loci (eQTLs) underlie a large 
proportion of GWAS associations
25,28
. We therefore searched for variants that were both in an IBD-
associated credible set with 50 or fewer variants, and the most significantly associated eQTL variant 
for a gene in a study
29
 of peripheral blood mononuclear cells (PBMCs) from 2,752 twins. Sixty-eight of 
the 76 regions with signals fine-mapped to ≤50 variants harboured at least one significant eQTL 
(affecting a gene within 1 megabase with P< 10
-5
). Despite this abundance of eQTLs in fine-mapped 
regions, only 3 credible sets included the most significantly associated eQTL variants, compared with 
3.7 expected by chance (Methods). Data from a more recent study
30
 using PBMCs from 8,086 
individuals did not yield a substantively different outcome, demonstrating a modest but non-significant 
enrichment (8 observed overlaps, 4.2 expected by chance, P= 0.06). Using a more lenient definition of 
overlap, requiring the lead eQTL variant to be in linkage disequilibrium (R
2
 > 0.4) with an IBD credible 
set variant, increased the number of potential overlaps but again these numbers were not greater than 
chance expectation. 
As PBMCs are a heterogeneous collection of immune cell populations, cell-type-specific signals or 
signals corresponding to genes expressed most prominently in non-immune tissues may be missed. 









), platelets, and three distinct intestinal locations 
(rectum, colon, and ileum) isolated from 350 healthy individuals (Methods). We observed a significant 
enrichment of credible single nucleotide polymorphism (SNP)/eQTL overlaps in CD4
+
 cells and ileum 
(Extended Data Table 2): 3 and 2 credible sets overlapped eQTLs, respectively, compared with 0.4 
and 0.3 expected by chance (P = 0.005 and 0.020). An enrichment was also observed for the naive 
CD14
+
 cells from another study
31
: 8 overlaps observed compared with 2.7 expected by chance (P= 
0.001). We did not observe enrichment of overlaps in stimulated (with interferon or lipopolysaccharide) 
CD14
+
 cells from the same source (Extended Data Table 2). 
We investigated eQTL overlaps more deeply by applying two co-localization approaches (one 
frequentist, one Bayesian, Methods) to our cell-separated dataset where primary genotype and 
expression data were available. We confirmed greater than expected overlap with eQTLs in CD4
+
 and 
ileum described above (Fig. 4 and Extended Data Table 2). These CD4
+
 co-localized eQTLs also had 
stronger overlap with CD4
+
 ChlP-seq peaks than our other credible sets, further supporting a 
regulatory causal mechanism. The number of co-localizations in other purified cell types and tissues 
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was largely indistinguishable from what we expected under the null using either method, except for 
moderate enrichment in rectum (4 observed and 1.4 expected, P= 0.039, Frequentist approach) and 
colon (3 observed and 0.8 expected, P= 0.04, Bayesian approach). Only two of these co-localizations 
corresponded to an IBD variant with causal probability >50% (Table 1 and Extended Data Fig. 4a). 
Discussion 
We have performed fine-mapping of 94 previously reported genetic risk loci for IBD. Rigorous quality 
control followed by an integration of three novel fine-mapping methods generated lists of genetic 
variants accounting for 139 independent associations across these loci. Our methods are concordant 
with an existing fine-mapping method
6
 (67 of 68 credible sets in single-signal regions overlap, 
including exact matches for all single variant credible sets), and provide extensions to support the 
phenotype assignment (Crohn's disease, ulcerative colitis, or IBD) and the conditional estimation of 
multiple credible sets in loci with multiple independent signals. The use of multiple methods allowed us 
to focus our downstream analyses on loci where the choice of fine-mapping method did not 
substantially alter conclusions about the biology of IBD. Our results improve on previous fine-mapping 
efforts using a preset linkage disequilibrium threshold
32
 (for example, r
2
 > 0.6) (Extended Data Fig. 5) 
by formally modelling the posterior probability of association of every variant. Much of this resolution 
derives from the very large sample size we used, because the number of variants in a credible set 
decreases with increasing significance (P= 0.0069). 
The high-density of genotyping also aids in improved resolution. For instance, the primary association 
at IL2RA has now been mapped to a single variant associated with Crohn's disease, rs61839660. This 
variant was not present in the HapMap 3 reference panel and was therefore not reported in earlier 
studies
3,33
 (nearby tagging variants, rsl2722489 and rsl2722515, were reported instead). Imputation 
using the 1000 Genomes Project reference panel and the largest assembled GWAS dataset
3
 did not 
separate rs61839660 from its neighbours (H.H., unpublished observations), owing to the loss of 
information in imputation using the limited reference. Only direct genotyping, available in the 
ImmunoChip high-density regions, allowed the conclusive identification of the causal variant. 
Accurate fine-mapping should, in many instances, ultimately point to the same variant across diseases 
in shared loci. Among our single-variant credible sets, we fine-mapped an ulcerative colitis association 
to a rare missense variant (1923 V) in IFIH1, which is also associated with type 1 diabetes
34
 with an 
opposite direction of effect (Supplementary Box). The intronic variant noted above (rs61839660, allele 
frequency = 9%) in IL2RA was also similarly associated with type 1 diabetes, again with a discordant 
directional effect
35
 (Supplementary Box). Simultaneous high-resolution fine-mapping in multiple 
diseases should therefore better clarify both shared and distinct biology. 
Resolution of fine-mapping can be further improved by leveraging linkage disequilibrium from other 
ethnicities
36
. However, the sample size from other ethnicities we have collected is small compared with 
European samples (9,846 across East Asian, South Asian, and Middle Eastern). Limited access to 
matched imputation reference panels from all cohorts and the fact that the smaller non-European sets 
are not from populations (for example, African-derived) with narrower linkage disequilibrium also 
suggest that gains in fine-mapping accuracy would be limited at this time. Ultimately this effort will be 
aided by more substantial investment in genotyping non-European population samples and by 
developing and applying more robust trans-ethnic fine-mapping algorithms. 
A new release of the 1000 Genomes (phase 3)
37
 and the UK10K
38 
project have introduced new 
variants that were not present in the reference panel in our study. Our major findings remain the same 
using this new reference panel: the 18 single-variant credible sets are not in high linkage 
disequilibrium (r
2
 > 0.95) with any new variants in either new dataset, and the 1,426 variants in IBD 
associations mapped to ≤50 variants are in high linkage disequilibrium with only 47 new variants (3.3% 
of the total size of these credible sets, Supplementary Table 1). Given that this release represents a 
near-complete catalogue of variants with minor allele frequency (MAF) > 1% in European populations, 
we believe our current fine-mapping results are likely to be robust, especially for common variant 
associations. High-resolution fine-mapping demonstrates that causal variants are significantly enriched 
for variants that alter protein-coding variants or disrupt transcription-factor binding motifs. Enrichment 
was also observed in H3K4mel marks in immune-related cell types and H3K27ac marks in sigmoid 
colon and rectal mucosal tissues, with Crohn's disease loci demonstrating a stronger immune 
signature and ulcerative colitis loci more enriched for gut tissues (P values 0.014, 0.0005, and 0.0013 
respectively for H3K4mel, H3K27ac, and H3K4me3; χ
2
 test). By contrast, overall enrichment of eQTLs 
is quite modest compared with previous reports and not seen strongly in excess of chance in our well-
refined credible sets (≤50 variants). This result emphasizes the importance of high-resolution mapping 
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and the careful incorporation of the high background rate of eQTLs. It is worth noting that evaluating 
the overlap between two distinct mapping results is fundamentally different from comparing genetic 
mapping results to fixed genomic features, and depends on both mappings being well resolved. 
Although these data challenge the hypothesis that easily surveyed baseline eQTLs explain a large 
proportion of non-coding GWAS signals, the modest excesses observed in smaller but cell-specific 
datasets suggest that much larger tissue- or cell-specific studies (and under the correct stimuli or 
developmental time points) will resolve the contribution of eQTLs to GWAS hits. 
Resolving multiple independent associations may often help target the causal gene more precisely. 
For example, the SMAD3 locus hosts a non-synonymous variant and a variant disrupting the 
conserved transcription-factor binding site (also overlapping the H3K27ac marker in gut tissues), 
unambiguously articulating a role in disease and providing an allelic series for further experimental 
inquiry. Similarly, the TYK2 locus has been mapped to a non-synonymous variant and a variant 
disrupting a conserved transcription-factor binding site (http:// finemapping.broadinstitute.org/). 
One-hundred and sixteen associations have been fine-mapped to ≤50 variants. Among them, 27 
associations contain coding variants, 20 contain variants disrupting transcription-factor binding motifs, 
and 45 are within histone H3K4mel- or H3K27ac-marked DNA regions. The best-resolved 
associations—45 variants having >50% posterior probabilities for being causal (Table 1)—are similarly 
significantly enriched for variants with known or presumed function from genome annotation. Of these, 
13 variants cause non-synonymous change in amino acids, 3 disrupt a conserved transcription-factor 
binding motif, 10 are within histone H3K4mel- or H3K27ac-marked DNA regions in disease-relevant 
tissues, and 2 co-localize with a significant cis-eQTL (Extended Data Fig. 4a). Risk alleles of these 
variants can be found throughout the allele frequency spectrum, with protein-coding variants having 
somewhat larger effects and more extreme risk allele frequencies (Extended Data Fig. 6a-c). 
 
Figure 4 | Number of credible sets that co-localize eQTLs. Distributions of the number of co-
localizations by chance (violins) and observed number of co-localizations with P values (dots). Both 
the background and the observed numbers were calculated using the 'Frequentist co-localization 
using conditional P values' approach (Methods). 
 
 
This analysis, however, leaves 21 non-coding variants (Extended Data Fig. 4b), all of which have 
>50% probabilities of being causal (five have >95%), that are not located within known motifs, 
annotated elements, or in any experimentally determined ChIP-seq peaks or eQTL credible sets yet 
discovered. While we have identified a statistically compelling set of genuine associations (often 
intronic or within 10 kb of strong candidate genes), we can make little inference about function. For 
example, the intronic single-variant credible set of LRRK2 has no annotation, eQTL, or ChlP-seq peak 
of note. This emphasizes the incompleteness of our knowledge about the function of non-coding DNA 
and its role in disease, and calls for comprehensive studies on transcriptomes and epigenomes in a 
wide range of cell lines and stimulation conditions. That most of the best-refined non-coding 
associations have no available annotation is perhaps sobering with respect to how well we may 
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currently be able to interpret non-coding variation in medical sequencing efforts. It does suggest, 
however, that detailed fine-mapping of GWAS signals down to single variants, combined with 
emerging high-throughput genome-editing methodology, may be among the most effective ways of 
advancing to a greater understanding of the biology of the non-coding genome. 
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Supplementary Information 
METHODS 
The study protocols were approved by the institutional review board at each centre involved with 
recruitment. Informed consent and permission to share the data were obtained from all subjects, in 
compliance with the guidelines specified by the recruiting centre's institutional review board. 
No statistical methods were used to predetermine sample size. The experiments were not 
randomized. The investigators were not blinded to allocation during experiments and outcome 
assessment. 
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Genotyping and quality control. We genotyped 35,197 unaffected and 35,346 affected individuals 
(20,155 Crohn's disease and 15,191 ulcerative colitis) using the ImmunoChip array. Genotypes were 
called using optiCall
40
 for 192,402 autosomal variants before quality control. We removed variants with 
missing data rate >2% across the whole dataset, or > 10% in any one batch, and variants that failed 
(false discovery rate (FDR) < 10
-5
 in either the whole dataset or at least two batches) tests for the 
following: (1) Hardy-Weinberg equilibrium in controls; (2) differential missingness between cases and 
controls; (3) different allele frequency across different batches in controls, Crohn's disease, or 
ulcerative colitis. We also removed non-coding variants that were present in the 1000 Genomes pilot 
stage but were not in the subsequent phase I integrated variant set (March 2012 release) and had not 
been in releases 2 or 3 of HapMap, as these mostly represented false positives from the 1000 
Genomes pilot, which often genotype poorly. Where a variant failed in exactly one batch, we set all 
genotypes to missing for that batch (to be reimputed later) and included the site if it passed in the 
remainder of the batches. We removed individuals that had >2% missing data, had significantly higher 
or lower (defined as FDR < 0.01) inbreeding coefficient (F), or were duplicated or related (PI_HAT ≥ 
0.4, calculated from the linkage disequilibrium pruned dataset described below), by sequentially 
removing the individual with the largest number of related samples until no related samples remained. 
We projected all remaining samples onto principal component axes generated from HapMap 3, and 
classified their ancestry using a Gaussian mixture model fitted to the European (CEU + TSI), African 
(YRI + LWK + ASW + MKK), East Asian (CHB + JPT), and South Asian (GIH) HapMap samples (CEU, 
Utah residents with Northern and Western European ancestry from the CEPH collection; TSI, Toscani 
in Italia; YRI, Yoruba in Ibadan, Nigeria; LWK, Luhya in Webuye, Kenya; ASW, African ancestry in 
southwest USA; MKK, Maasai in Kinyawa, Kenya; CHB, Han Chinese in Beijing, China; JPT, 
Japanese in Tokyo, Japan; GIH, Gujarati Indians in Houston, Texas). We removed all samples that 
were classified as non-European, or that lay more than 8 standard deviations from the European 
cluster. After quality control, there were 67,852 European-derived samples with valid diagnoses 
(healthy control, Crohn's disease, or ulcerative colitis), and 161,681 genotyped variants available for 
downstream analyses. 
Linkage disequilibrium pruning and principal component analysis. From the clean dataset we 
removed variants in long-range linkage disequilibrium
41
 or with MAF <0.05, and then pruned three 
times using the '-indep' option in PLINK (with window size of 50, step size of 5 and VIF threshold of 
1.25). Principal component axes were generated within controls using this linkage disequilibrium 
pruned dataset (18,123 variants). The axes were then projected to cases to generate the principal 
components for all samples. The analysis was performed using our in-house C code 
(https://github.com/hailianghuang/efficientPCA) and LAPACK package
42 
for efficiency. 
Controlling for population structure, batch effects, and other confounders. We used 2,853 
'background SNPs' present on the ImmunoChip but not known to be associated with immune 
disorders to calculate the genomic inflation factor λGC. After including the first five principal 
components calculated above as covar-iates, λGC = 1.29, 1.25, and 1.31 for Crohn's disease, ulcerative 
colitis, and IBD (adding additional principal components did not further reduce λGC Extended Data 
Table 3a). Because our genotype data were processed in 15 batches with variable ratios of cases to 
controls, we conducted two analyses to ensure possible batch effects were adequately controlled. 
First, we split the samples into a 'balanced' cohort with studies having both cases and controls, and an 
'imbal-anced' cohort with studies having exclusively cases or controls (Extended Data Table 1). As λGC 
under polygenic inheritance scales with the sample size
43
, we randomly down-sampled the full dataset 
to match the sample size of the balanced and the imbalanced cohorts, respectively. We tested for 
association in these subsets of our data (and included batch identifier as a covariate in the balanced 
cohort), and found the λGC from the balanced and imbalanced cohorts to be within the 95% confidence 
interval of size-matched values from our full data, suggesting that batch effects were not 
systematically inflating our association statistics (Extended Data Table 3b). We also performed a 
heterogeneity test for the odds ratio of lead variants in each credible set using the balanced and 
imbalanced cohorts, and observed no significant heterogeneity after Bonferroni correction 
(Supplementary Table 3). 
We next sought to disentangle the contributions of polygenic inheritance and uncorrected population 
structure in our observed λGC. Linkage disequilibrium score regression
44
 is able to differentiate these 
two effects, but requires genome-wide data, so was not possible in our ImmunoChip dataset. Instead, 
we compared λGC and λ1000 values calculated using the same set of background SNPs from the largest 
IBD meta-analysis with genome-wide data
45
. For both Crohn's disease and ulcerative colitis, the λ1000 
values in our ImmunoChip study (1.012 and 1.012) were equal to or less than those in the genome-
wide study (1.016 and 1.012). Furthermore, linkage disequilibrium score regression on the genome-
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wide data showed that most inflation was caused by polygenic risk (linkage disequilibrium score 
intercept = 1.09 for both Crohn's disease and ulcerative colitis, compared with λGC= 1-23 and 1.29). 
Together, these results show that our residual inflation is consistent with polygenic signal and modest 
residual confounding. We tested what effect correcting for the linkage disequilibrium score intercept of 
1.09 would have on posterior probabilities and credible sets, and found no major differences compared 
with uncorrected values. The full comparison of A values is shown in Extended Data Table 3c. 
Imputation. Imputation was performed separately in each ImmunoChip autosomal high-density region 
(185 total) from the 1000 Genomes phase I integrated haplotype reference panel. To prevent the edge 
effect, we extended each side of the high-density regions by 50 kbp. Two imputations were performed 
sequentially (Extended Data Fig. 2) using software and parameters as described below. The first 
imputation was performed immediately after the quality control, from which the major results were 
manually inspected ('Manual cluster plot inspection section in Methods). The second imputation was 
performed after removing variants that failed the manual cluster plot inspection. We used 
SHAPEIT
46,47 
(versions: first imputation, v2.r644; second imputation, v2.r769) to pre-phase the 
genotypes, followed by IMPUTE2
13,14
 (versions: first, 2.2.2; second, 2.3.0) to perform the imputation. 
The reference panels were downloaded from the IMPUTE2 website (first, March 2012 release; 
second, December 2013 release). After the second imputation, there were 388,432 variants with good 
imputation quality (INFO > 0.4). These include 99.9% of variants with MAF ≥ 0.05,99.3% of variants 
with 0.05 > MAF ≥ 0.01, and 63.0% of variants with MAF < 0.01 (Extended Data Fig. 6d-f), with similar 
success rates both for coding and for non-coding variants, making it unlikely that missing variants 
substantially affected our fine-mapping conclusions. 
Manual cluster plot inspection. Variants that had posterior probability greater than 50% or in 
credible sets mapped to ≤ 10 variants were manually inspected using Evoker version 2.2 (ref. 48). 
Each variant was inspected by three independent reviewers (ten reviewers participated) and scored as 
pass, fail, or maybe. Reviewers were blinded to the posterior probability of these variants. We 
removed variants that received one or more fails, or received fewer than two passes. Two hundred 
and twenty out of 276 inspected variants passed this inspection, and 53 out of 56 failed variants were 
restored by imputation. There was no difference in MAF between the failed and the passed variants 
(P=0.66). A further cluster plot inspection flagged two additional failed variants after removing the 
failed variants from the first inspection and re-doing the imputation and analysis. Dramatic clustering 
errors accounted for 27 out of 58 flagged variants, which were eliminated from final credible sets. The 
remaining 31 had only minor issues, and the imputed data for these remained in our final credible sets, 
with marginally smaller posteriors (mean of the difference 9.8%, P=0.06, paired t-test). 
Establishing a P value threshold. We used a multiple-testing-corrected P value threshold for 
associations of 1.35 x 10
-6
, which was established by permutation. We generated 200 permuted 
datasets by randomly shuffling phenotypes across samples and performed association analyses for 
each permutation across all variants in high-density regions that overlapped IBD-associated loci
3
. We 
stored (1) all the point-wise P values (αS), as well as (2) the 'best' P values (αB) of each of the 200 
permuted datasets. We then computed the empirical, experiment-wide P value (αM) (corrected for 
multiple testing) for each of the tests as its rank/200 with respect to the 200 αB∙ We then estimated the 
number of independent tests performed in the studied regions, n, as the slope of the regression of 
log(1 - αM) on log(1 - αS), knowing that αM= 1 - | ( 1 – αS)
n
, yielding a value of 37,056. The P value 
threshold was determined as 0.05/n ≈ 1.35 x 10
-6
. Detecting and fine-mapping association signals. 
We used three fine-mapping methods (Supplementary Methods) to detect independent signals and 
create credible sets across 97 ImmunoChip autosomal high-density regions that contained at least one 
variant with P < 1.35 x 10
-6
. Our process for merging the results of the three methods is described 
below and illustrated in Fig. la. 
1. We merged signals from different methods if their credible sets overlapped. To ensure a 
conservative credible set, this new merged credible set included all variants from all merged signals 
(the union of constituent credible sets). We assigned each variant in the merged credible sets a 
posterior probability equal to the average of the probabilities from the methods that reported this 
signal. To filter out technical artefacts, we required genotyped variants in small credible sets to pass 
manual cluster plot inspection (see above) and all imputed variants to have INFO > 0.4. For signals 
reported by only one or two methods that contained only imputed variants (that is, no directly 
genotyped variants), we additionally required at least one variant with INFO > 0.8 and MAF > 0.01. 
2. We next assigned each signal to a provisional combination of lead variant and phenotype (Crohn's 
disease, ulcerative colitis, or IBD) that maximized the marginal likelihood of equation (8) in 
Supplementary Methods. 
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3. At loci with more than one signal, we built a multivariate model with all signals reported by all three 
methods, and tested all possible combinations of adding signals reported by one or two methods, as 
long as they still had P < 1.35 x 10
-6 
when jointly fitted in the multi-signal model. We selected the 
combination with the highest joint marginal likelihood (equation (8) in Supplementary Methods). 
Phenotype assignment of signals. The provisional phenotype assignment, performed during the 
signal merging described above, was merely a point estimate and did not capture the uncertainty 
associated with the phenotypic assignment. We therefore recomputed the assignment of each signal 
as Crohn's-disease-specific, ulcerative-colitis-specific, or shared using the Bayesian multinomial 
model from fine-mapping method 2, empirical covariance prior with Laplace approximation
49
, as it was 
designed to assess evidence of sharing in the presence of potentially correlated effect sizes. For the 
lead variant for each credible set, we calculated the marginal likelihoods as in equation (13) from 
Supplementary Methods, restricting either βUC = 0 (for the Crohn's-disease-only model) or βCD = 0 (for 
the ulcerative-colitis-only model), as well as using the unconstrained prior (for the associated-to-both 
model). We then calculated the log(Bayes factor) in favour of sharing; that is, the log of the ratio of 
marginal likelihoods between the associated-to-both model and the best of the single-phenotype 
associated models. These sharing log(Bayes factors) are given in Supplementary Table 1 (column 
'sharingBF'), and are a probabilistic assessment of phenotype assignment: for instance, the log(Bayes 
factor) of 97.4 for the primary signal at IL23R suggests a very high certainty that this signal is shared 
across both Crohn's disease and ulcerative colitis, whereas the log(Bayes factor) of 0.4 for the primary 
signal at FUT2 is more ambiguous. In addition to providing the log(Bayes factor) itself, we also applied 
a log(Bayes factor) cut-off of 10 to select variants with strong evidence of being shared across 
phenotypes. 
Final filters. These procedures generated some signals where all three methods largely agreed, and 
some where they differed. While the signals where the methods disagree are of interest for methods 
development, here we chose to focus on the most concordant signals, as they are most 
straightforward to interpret biologically. We therefore discarded all signals found by only one method 
(which completely removed one locus), and two loci where the ratio of marginal likelihoods (equation 
(8) in Supplementary Methods) for the best model and the second-best model was <10 
(Supplementary Notes). After these filters (Extended Data Fig. 7), we considered 139 signals from 94 
regions (containing a total of 181,232 variants) to be confidently fine-mapped, and took them forward 
for subsequent analysis. 
Estimating the variance explained by the fine-mapping. We used a mixed-model framework to 
estimate the total risk variance attributable to the IBD risk loci, and to the signals identified in the fine-
mapping. We used the GCTA software package
50
 to compute a gametic relationship matrix (G-matrix) 
using genotype dosage information for the genotyped variants in the high-density regions (which we 
will call GHD)∙ We then fitted a variety of variance component models by restricted maximum likelihood 
analysis using an underlying liability threshold model implemented with the DMU package
51
. The first 
model was a standard heritability mixed-model that included fixed effects for five principal components 
(to correct for stratification) and a random effect summarizing the contribution of all variants in the fine-
mapping regions, such that the liabilities across all individuals were distributed according to 
 
where λ1 is thus the variance explained by all variants in fine-mapping regions, which we estimated. 
We then fitted a model that included an additional random effect for the contribution of the lead 
variants that had been specifically identified (with G-matrix GSignals), such that the liability was 
distributed as 
 
The variance explained by the signals under consideration was then given by the reduction in the 
variance explained by all variants in the fine-mapping regions between the two models . We used 
this approach to estimate what fraction of this variance was accounted for by (1) the single strongest 
signals in each region (as would be typically done before fine-mapping), or (2) all signals identified in 
fine-mapping. We used Cox and Snell's method
52
 to estimate the variance explained across individual 
signals (Extended Data Fig. 3b) for computational efficiency. 
Overlap between transcription-factor binding motifs and causal variants. For each motif in the 
ENCODE transcription factor ChlP-seq data (http://compbio. mit.edu/encode-motifs/, accessed 
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November 2014)
20
, we calculated the overall information content as the sum of information content for 
each position
53
, and only considered motifs with overall information content ≥ 14 bits (equivalent to 
seven perfectly conserved positions). For every variant in a high-density region, we determined 
whether it created or disrupted a motif at a high-information site (information content ≥ 1.8). 
Overlap between epigenetic signatures and causal variants. For each combination of 120 tissues 
and 3 histone marks (H3K4mel, H3K4me3, and H3K27ac) from the Roadmap Epigenome Project, we 
calculated an overlap score, equal to the sum of fine-mapping posterior probabilities for all variants in 
peaks of that histone mark in that tissue. We generated a null distribution of this score for each tissue/ 
mark by shifting chromatin marks randomly (between 0 bp and 44.53 megabase pairs, the length of all 
high-density regions) and circularly (peaks at the end of the region shifted to the beginning of the 
region) over the high-density regions while keeping the same inter-peak distances. To summarize 
these correlated results across many cell and tissue types, we defined a set of 'core' H3K4mel 
immune and H3K27ac gut peaks as sets of overlapping peaks in cells that showed the strongest 
enrichment. Intersects were made using bedtools version 2.24.0 default settings
54
. We selected six 
immune cell types for H3K4me 1 and three gut cell types for H3K27ac (Supplementary Table 2). We 
also chose controls (Supplementary Table 2) from non-immune and non-gut cell types with similar 
density of peaks in the fine-mapped regions compared with immune/gut cell types to confirm the 
tissue-specificity of the overlap. We used the phenotype assignments (described above) in dissecting 
the enrichment for the Crohn's disease and ulcerative colitis signals. Sixty-five Crohn's disease and 21 
ulcerative colitis signals that were mapped to ≤50 variants were used in this analysis. 
Published eQTL summary statistics. We used eQTL summary statistics from three published 
studies. (1) Peripheral blood eQTLs from ref. 29 of 2,752 twins, reporting loci with MAF > 0.5%. 
Imputation was performed using the 1000 Genomes reference panel
11
. (2) Peripheral blood eQTLs 
from ref. 30 of 8,086 individuals, including variants with MAF > 5%. Imputation was performed using 




 monocyte eQTLs from Supplementary 
Table 2 in ref. 31, comprising 432 European individuals, measured in a naive state and after 
stimulation with interferon-γ or lipopolysac-charide (for 2 or 24h), reporting loci with MAF > 4% and 
FDR < 0.05. Imputation was performed using the 1000 Genomes reference panel
10
. Processing and 
quality control of new eQTL ULg dataset. A detailed description of the ULg dataset is in preparation 
(Y.M. et al, in preparation). Briefly, we collected venous blood and intestinal biopsies at three locations 
(ileum, transverse colon, and rectum) from 350 healthy individuals of European descent, average age 
54 (range 17-87), 56% female. SNPs were genotyped on Illumina Human OmniExpress version 1.0 
arrays interrogating 730,525 variants, and SNPs and individuals were subjected to standard quality 
control procedures using call rate, Hardy-Weinberg equilibrium, MAF ≥ 0.05, and consistency between 
declared and genotype-based sex as criteria. We further imputed genotypes at ~7 million variants on 
the entire cohort using the Impute2 software package
13
 and the 1,000 Genomes Project as reference 
population (phase 3 integrated variant set, released 12 October 2014)
11,14
. From the blood, we purified 
CD4+, CD8+, CD19+, CD14+, and CD 15
+
 cells by positive selection, and platelets (CD45
-
) by 
negative selection. RNA from all leucocyte samples and intestinal biopsies was hybridized on Illumina 
Human HT-12 arrays version 4. After standard quality control, raw fluorescent intensities were 
variance stabilized
56
 and quantile normalized
57
 using the lumi R package
58
, and were corrected for 
sex, age, smoking status, number of probes with expression level significantly above background as 
fixed effects and array number (sentrix id) as the random effect. For each probe with measurable 
expression (detection P value < 0.05 in >25% of samples), we tested for cis-eQTLs at all variants 
within a 500 kbp window. The nominal P value of the best SNP within a cis-window was Sidak-
corrected for the window-specific number of independent tests. The number of independent tests in 
each window was estimated exactly in the same manner as for the number of independent tests for 
fine-mapping methods ('Establishing a P value threshold' section in Methods). We estimated false 
discovery rates (q values) from the resulting P values across all probes using the qvalue R package
59
. 
Four hundred and eighty cis-eQTL with FDR ≤ 0.10 for which the lead SNPs (that is, the SNP yielding 
the best P value for the αs-eQTL) mapped within the 97 high-density regions (94 fine-mapped plus 3 
unresolved) were retained for further analyses. 
Naive co-localization using lead SNPs. We calculated the number of IBD credible sets containing a 
lead eQTL variant in a particular tissue ('observed'). This number was then compared with the 
background number of overlaps ('expected'): 
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where Ni, is the total number of variants in region i in 1,000 genomes with an allele frequency greater 
than a certain threshold (equal to the threshold used for the original eQTL study), Ci is the number of 
these variants that lie in IBD credible sets, and S is a set of regions that have at least one significant 
eQTL. We simulated 1,000 trials per region with binomial probability equal to the regional background 
overlap rate:  Empirical P values were estimated by comparing the observed number of 
overlaps with the simulated number of the overlaps. More specifically, the P value was defined as the 
proportion of trails having equal or more overlaps in the simulations than the observed. 
Frequentist co-localization using conditional P values. We next used conditional association to 
test for evidence of co-localization, as described in ref. 25. This method compares the P value of 
association for the lead SNP of an eQTL before and after conditioning on the SNP with the highest 
posterior in the credible set, and measures the drop in -log(P). An empirical P value for this drop is 
then calculated by comparing it to the drop for all variants in the high-density region. Because this 
method requires full genotypes, we could only apply it to the ULg dataset (MAP > 5%). An empirical P 
value ≤ 0.05 was considered as evidence that the corresponding credible set was co-localized with the 
corresponding cis-eQTL. To evaluate whether our fine-mapping associations co-localized with cis-
eQTL more often than expected by chance, we counted the number of credible sets affecting at least 
one cis-eQTL with P ≤ 0.05, and compared how often this number was matched or exceeded by 1,000 
sets of variants that were randomly selected yet distributed among the loci in accordance with the real 
credible sets. The number of variants per set was same as the number of credible sets in this eQTL 
analysis (MAP matched, size ≤ 50), shown in Extended Data Table 2. Bayesian co-localization 
using Bayes factors. Finally, we used the Bayesian co-localization methodology described in ref. 60, 
modified to use the credible sets and posteriors generated by our fine-mapping methods (similarly only 
applicable to the ULg full genotype data). The method takes as input a pair of IBD and eQTL signals, 




, and posteriors for each 
variant Credible sets and posteriors were generated for eQTL signals using 
the Bayesian quantitative association mode in SNPTest (with default parameters), with credible sets in 
regions with multiple independent signals generated conditional on all other signals. Our method 
calculated a Bayes factor (BF) summarizing the evidence in favour of a co-localized model (that is, a 
single underlying causal variant between the IBD and eQTL signals) compared with a non-co-localized 
model (where different causal variants were driving the two signals), given by the ratio of marginal 
likelihoods 
 
The marginal likelihood for the co-localized model (that is, hypothesis H4 in ref. 60) is given by 
 
and the marginal likelihood for the model where the signals are not co-localized (that is, hypothesis H3) 
is given by: 
 
In both cases, N is the total number of variants in the region. We only counted towards N variants 
having r
2
 > 0.2 with either the lead eQTL variant or the lead IBD variant. 
To measure enrichment in co-localization BFs compared with the null, we performed a permutation 
analysis. In this analysis, we randomly reassigned eQTL signals to new fine-mapping regions to 
generate a set of simulated null datasets. This was done using the following scheme on variants and 
credible sets with the same MAP cut-off as the eQTL dataset (ULg, MAP > 5%). (1) Estimate the 
standardized effect size βg for each eQTL signal g, equal to standard deviation increase in gene 
expression for each dose of the minor allele. (2) Randomly reassign each eQTL signal to a new fine-
mapping region, and then select a new causal variant with a MAP within 1% of the lead variant from 
the real signal. If multiple such variants exist, select one at random. If no such variants exist, pick the 
variant with the closest MAP. (3) Generate new simulated gene expression signals for each individual 
from Normal , where xj is the individual's minor allele dosage at the new causal variant 
and/is the MAP. (4) Carry out fine-mapping and calculate co-localization Bayes factors for each pair of 
(real) IBD signals and (simulated) eQTL signals. (5) Repeat stages (2)-(4) 1,000 times for each tissue 
Published in: Nature (2017), vol. 547, pp. 173-178 doi:10.1038/nature22969 
Status: Postprint (author’s version) 
type. We can use these permuted Bayes factors to calculate P values for each IBD credible set, given 
by the proportion of time the permuted Bayes factors were as large or greater than the one observed 
in the real dataset. To generate a high-quality set of co-localized eQTL and IBD signals, we take all 
IBD signals that have the co-localization BF > 2, P < 0.01, and r
2
 (with the eQTL variant) > 0.8. 
Code availability. Computer code used in this study is provided in the 'Software availability' sections 
in the Supplementary Methods. 
Data availability. The data that support the findings of this study are available from the International 
Inflammatory Bowel Disease Genetics Consortium but restrictions apply to the availability of these 
data, which were used under licence for the current study, and so are not publicly available. Data are, 
however, available from the corresponding authors upon reasonable request and with the permission 
of the International Inflammatory Bowel Disease Genetics Consortium. 
 
 
Extended Data Figure 1 | Power of the fine-mapping analysis. Power (γ axis) to identify the causal 
variant in a correlated pair (strength of correlation shown by colour) increases with the significance of 
the association (x axis), and therefore with sample size and effect size. The vertical dashed line shows 
the genome-wide significance level. To estimate the relationship between the strength of association 
and our ability to fine-map it, we assume that the association has only two causal variant candidates, 
and we define the signal as successfully fine-mapped if the ratio of Bayes factors between the true 
causal variant and the non-causal variant was greater than 10 (a 91% posterior, assuming equal priors 
for the two candidate variants). Using equation (8) in Supplementary Methods, we have 
 





in which λ is the χ
2
 statistic of the lead variant and r is the correlation coefficient between the two 
variants. Because of the additive property of the χ
2
 distribution, logBF follows a non-central χ
2
 
distribution with 1 degree of freedom and non-centrality parameter λ(l — r
2
)/2. Therefore, the power 
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Extended Data Figure 2 | Procedures in the fine-mapping analysis. Details for each stage are 
described in Methods. The dashed line means the imputation was performed only once after the 
manual inspection (not iteratively). 
 
 
Extended Data Figure 3 | Variance explained. Variance explained by secondary, tertiary,... variants 
as a fraction of the primary signal at each locus. 
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Extended Data Figure 4 | Functional annotations, a, Functional annotation for 45 variants having 
posterior probability > 50%. b, Functional annotation for 116 association signals fine-mapped to ≤50 











, platelets) and 'Gut' (ileum, transverse colon, and rectum). The 
eQTLs were generated from the ULg dataset using the 'Frequentist co-localization using conditional P 
values' approach (Methods). 
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Extended Data Figure 5 | Size of credible sets. Comparison of credible set sizes for primary signals 
using each of our fine-mapping methods (methods 1, 2, and 3), the combined approach (as adopted in 
final results) and the approach described in ref. 6 (γ axis) and the r
2
 > 0.6 cut-off (x axis). Fine-
mapping maps most signals to smaller numbers of variants. The trend line (blue) and the confidence 
interval (grey) were calculated using the geom_smooth function in the R ggplot2 package using the 
linear model. 
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Extended Data Figure 6 | Distributions of the allele frequency and the imputation quality, a-c, 
Distribution of the risk allele frequency for 45 variants having >50% posterior probability plotted 
against (a) posterior probability, (b) significance of the association as -log10(P), and (c) odds ratio of 
the association. Variants are colour coded according to their functions. Odds ratio for IBD associations 
was the larger of odds ratios for Crohn's disease and ulcerative colitis, d-f, Distribution of imputation 
quality (INFO measure from the IMPUTE2 program) for variants having MAF ≥ 5% (d), between 5% 




Extended Data Figure 7 | Merging and adjudicating signals across methods. The number of 
signals for each method is shown in the brackets, and for each method a black bar indicates a signal 
with P < 1.35 x 10
-6
, and a grey bar a signal that does not reach that threshold. The coloured bar 
shows the final status of each signal after merging and model selection (Methods). Label 'low INFO' 
corresponds to INFO < 0.8 (the threshold used for signals reported by one or two methods), and 'rare 
and imputed' to MAF < 0.01 and no genotyped variants in the credible set, regardless of INFO 
(Methods). 
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Extended Data Table 1 | Study samples 
Batch Control CD UC Cohort 
IMSGC 5740 0 0 imbalanced 
NIDDK 1786 3653 3020 balanced 
D. Ellinghaus 4559 2696 1006 balanced 
E. Theatre 713 1109 559 balanced 
H. Huang 3 551 316 imbalanced 
J. Barrett 4397 2715 2835 balanced 
K. Fransen 1598 1234 430 balanced 
L. Jostins 1354 1252 1063 balanced 
P. Gregersen 1611 0 0 imbalanced 
R. Duerr 1696 321 1611 balanced 
S. Rich 4259 0 0 imbalanced 
S. Sommeren 107 77 201 balanced 
S. Vermeire 922 1539 838 balanced 
T. Balschun 5511 1882 1683 balanced 
T. Haritunians 1 1938 1066 imbalanced 
Genotyped samples in each batch for healthy controls (Control), Crohn's disease (CD), and ulcerative colitis (UC). Batches were 
grouped into cohorts for further analysis ('Controlling for population structure, batch effects, and other confounders' section in 
Methods). 
 
Extended Data Table 2 | Co-localization with eQTL 
Tissue                                     









whole blood                             
Naive 
3 3.7 0.746 GODOT 0.005 113 
whole blood 8 4.2 0.060 Westra 0.05 95 
CD14+ naïve 8 2.7 0.001 Fairfax 0.04 98 
CD14+ FN stimulated 4 3.2 0.398 Fairfax 0.04 98 
CD14+ LPS 2h stimulated 1 2.1 0.869 Fairfax 0.04 98 
CD14+ LPS 24h stimulated 5 2.5 0.106 Fairfax 0.04 98 
CD4+ 3 0.4 0.005 ULg 0.05 95 
CD8+ 1 0.3 0.306 ULg 0.05 95 
CD14+ 0 0.2 1.000 ULg 0.05 95 
CD15+ 1 0.2 0.199 ULg 0.05 95 
CD19+ 0 0.1 1.000 ULg 0.05 95 
platelets 0 0.0 1.000 ULg 0.05 95 
ileum 2 0.3 0.020 ULg 0.05 95 
colon 1 0.2 0.202 ULg 0.05 95 
rectum 1 0.2 0.189 ULg 0.05 95 
CD4+                                        
Frequentist 
6 1.9 0.013 ULg 0.05 95 
CD8+ 3 1.5 0.186 ULg 0.05 95 
CD14+ 4 2.3 0.180 ULg 0.05 95 
CD15+ 1 1.8 0.863 ULg 0.05 95 
CD19+ 0 1.4 1.000 ULg 0.05 95 
platelets 0 0.1 1.000 ULg 0.05 95 
ileum 4 1.1 0.018 ULg 0.05 95 
colon 3 1.7 0.216 ULg 0.05 95 
rectum 4 1.4 0.039 ULg 0.05 95 
CD4+                                      
Bayesian 
4 1.0 0.010 ULg 0.05 95 
CD8+ 1 0.8 0.566 ULg 0.05 95 
CD14+ 1 0.9 0.595 ULg 0.05 95 
CD15+ 0 0.7 1.000 ULg 0.05 95 
CD19+ 0 0.6 1.000 ULg 0.05 95 
platelets 0 0.1 1.000 ULg 0.05 95 
ileum 2 0.4 0.069 ULg 0.05 95 
colon 3 0.8 0.040 ULg 0.05 95 
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rectum 2 0.6 0.124 ULg 0.05 95 
The number of IBD credible sets that co-localize with eQTLs using the naive, frequentist, and Bayesian approaches. Significant 
observations are set in bold type. 'Number of credible sets' reports the number of credible sets that have MAF above the cut-off. 
IFN, interferon-γ; LPS, lipopolysaccharide. 
 
Extended Data Table 3 | Genomic inflation 
a 
 CD UC IBD 
PC 1-4 1.41 1.31 1.38 
PC 1-5 1.29 1.25 1.31 
PC 1-6 1.28 1.25 1.32 
    
b    
 CD UC IBD 
Balanced cohort 1.24 1.21 1.20 
Down-sampled (balanced) 1.24 (1.14-1.36) 1.21 (1.11-1.31) 1.23 (1.14-1.36) 
Imbalanced cohort 1.02 1.08 1.00 
Down-sampled (imbalanced) 1.08 (0.97-1.23) 1.04 (0.96-1.16) 1.07 (0.95-1.21) 
All samples 1.29 1.25 1.31 
 
c 
  genome-wide "background SNPS" 
 LDscore intercept λGC λ1000 λGC λ1000 
CD: Immunochip (this study) - - - 1.29 1.012 
CD: GWAS 1.09 1.23 1.014 1.28 1.016 
UC: Immunochip (this study) - - - 1.25 1.012 
UC: GWAS 1.09 1.29 1.016 1.21 1.012 
      
Genomic inflation factors and linkage disequilibrium score regression intercept for Crohn's disease (CD), ulcerative colitis (UC) 
and both (IBD). a, Genomic inflation factors using the first four, five, and six principal components. The factors were calculated 
using 2,853 background variants from the ImmunoChip. b, Genomic inflation factors for subsets of the data (using five principal 
components for the same 2,853 background variants). Balanced, imbalanced, and down-sampled cohorts are defined in 
Methods. Numbers in brackets indicate the 95% confidence interval for the inflation factors (only estimated for the down-
sampled cohorts), c, Linkage disequilibrium score regression intercept and genomic inflation factors (λGC and λ1000) from the 
largest IBD meta-analyses with genome-wide data (CD: GWAS and UC: GWAS). 
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